Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437

Watchlist Manager
Harbin Gloria Pharmaceuticals Co Ltd Logo
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Watchlist
Price: 2.68 CNY
Market Cap: 6.1B CNY
Have any thoughts about
Harbin Gloria Pharmaceuticals Co Ltd?
Write Note

Harbin Gloria Pharmaceuticals Co Ltd
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Harbin Gloria Pharmaceuticals Co Ltd
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Net Change in Cash
-ÂĄ468m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Change in Cash
ÂĄ3.3B
CAGR 3-Years
N/A
CAGR 5-Years
37%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Change in Cash
ÂĄ6.1B
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Change in Cash
ÂĄ4.4B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Change in Cash
ÂĄ359.1m
CAGR 3-Years
-67%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Change in Cash
-ÂĄ609m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Harbin Gloria Pharmaceuticals Co Ltd
Glance View

Market Cap
6.1B CNY
Industry
Pharmaceuticals

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing and currently employs 4,769 full-time employees. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
2.32 CNY
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Harbin Gloria Pharmaceuticals Co Ltd's Net Change in Cash?
Net Change in Cash
-468m CNY

Based on the financial report for Sep 30, 2024, Harbin Gloria Pharmaceuticals Co Ltd's Net Change in Cash amounts to -468m CNY.

What is Harbin Gloria Pharmaceuticals Co Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
-2%

Over the last year, the Net Change in Cash growth was -10%.

Back to Top